In a recent article for the Milken Institute Review, former New York Times writer Larry Fisher raises urgent concerns about the quality and safety of generic drugs in the U.S., citing inadequate government oversight and the unintended consequences of the Hatch-Waxman Act. With generics now comprising 90% of the U.S. drug market, issues such as contamination, mislabeling, and supply chain opacity—especially from manufacturers in India and China—pose a growing threat to public health.

The piece explores independent solutions to these challenges, including drug certification programs and third-party verification. It highlights Valisure as a leading example: an independent analytical laboratory with its own pharmacy, Valisure batch-tests medications for purity and dosage before dispensing certified generics directly to consumers.

The article also features insights from Stanford professor Kevin Schulman, who found substandard blood pressure medications in Nigeria, reinforcing the global scope of the problem. Fisher encourages consumers to seek out certified generics, request brand-name drugs when possible, and envisions a future where retail giants like Amazon or Walmart could play a role in delivering safer pharmaceutical options.

Read the full article via Milken Institute Review →

‍

In a recent article for the Milken Institute Review, former New York Times writer Larry Fisher raises urgent concerns about the quality and safety of generic drugs in the U.S., citing inadequate government oversight and the unintended consequences of the Hatch-Waxman Act. With generics now comprising 90% of the U.S. drug market, issues such as contamination, mislabeling, and supply chain opacity—especially from manufacturers in India and China—pose a growing threat to public health.

The piece explores independent solutions to these challenges, including drug certification programs and third-party verification. It highlights Valisure as a leading example: an independent analytical laboratory with its own pharmacy, Valisure batch-tests medications for purity and dosage before dispensing certified generics directly to consumers.

The article also features insights from Stanford professor Kevin Schulman, who found substandard blood pressure medications in Nigeria, reinforcing the global scope of the problem. Fisher encourages consumers to seek out certified generics, request brand-name drugs when possible, and envisions a future where retail giants like Amazon or Walmart could play a role in delivering safer pharmaceutical options.

Read the full article via Milken Institute Review →

‍